RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:213807

Leiomyosarcoma of the cervix uteri

medium confidenceDisorder

Also known as: Cervical leiomyosarcoma

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

316

75.5th percentile

Trials

0

Interventional, condition-specific

Researchers

1,057

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Leiomyosarcoma of the cervix uteri is a rare, malignant mesenchymal tumor of smooth muscle origin, macroscopically appearing as a large, poorly circumscribed mass, often protruding from the cervical canal or expanding it circumferentially. The most common presenting symptoms are vaginal discharge or bleeding, pain in the lower abdomen and a bulky cervical mass. There is a reported tendency to metastatsize hematogenously, especially to the lungs, peritoneum, bones and the liver.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

cervical leiomyosarcoma · leiomyosarcoma of uterine cervix · uterine cervix leiomyosarcoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    316 matched papers (164 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 140 for broader category leiomyosarcoma

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

316

316 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

316 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

164 in the last 10 years · medium confidence · 75.5th percentile (publications denominator)

Phrase hits: 316 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,057

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Balodis A3 papers · 2026

    Institute of Diagnostic Radiology, Pauls Stradins Clinical University Hospital, 13 Pilsonu Street, LV-1002 Riga, Latvia

    Papers in Europe PMC
  2. 02
    Mahmajeva O3 papers · 2026

    Institute of Pathology, Pauls Stradins Clinical University Hospital, 13 Pilsonu Street, LV-1002 Riga, Latvia

    Papers in Europe PMC
  3. 03
    Mikijanska M3 papers · 2026

    Institute of Diagnostic Radiology, Pauls Stradins Clinical University Hospital, 13 Pilsonu Street, LV-1002 Riga, Latvia

    Papers in Europe PMC
  4. 04
    Özütemiz C3 papers · 2026

    Department of Radiology, University of Minnesota, Minneapolis, MN 55455, USA

    Papers in Europe PMC
  5. 05
    Rate E3 papers · 2026

    Clinic of Otolaryngology, Pauls Stradins Clinical University Hospital, 13 Pilsonu Street, LV-1002 Riga, Latvia

    Papers in Europe PMC
  6. 06
    Tumelkans R3 papers · 2026

    Faculty of Medicine, Riga Stradins University, 16 Dzirciema Street, LV-1007 Riga, Latvia

    Papers in Europe PMC
  7. 07
    Abeillon J2 papers · 2025

    Hospices Civils de Lyon, Hôpital Louis Pradel, Service d'Endocrinologie, Bron, France.

    Papers in Europe PMC
  8. 08
    Albert A2 papers · 2020

    Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, USA. ashley.grv@gmail.com.

    Papers in Europe PMC
  9. 09
    Benfadil D2 papers · 2025

    ENT and Head and Neck Surgery Department, University Hospital Center Mohammed VI, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco.

    Papers in Europe PMC
  10. 10
    Cacciotti G2 papers · 2023

    Department of Neurosurgery, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 140 trials are registered for leiomyosarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

140 interventional trials matched leiomyosarcoma, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: leiomyosarcoma

140

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

General rare disease registries you may be eligible for

These studies enroll across many rare conditions. They are not counted as evidence that anyone is studying this specific disease.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Leiomyosarcoma of the cervix uteri" OR "Leiomyosarcoma of cervix uteri" OR "Cervical leiomyosarcoma" OR "leiomyosarcoma of uterine cervix" OR "leiomyosarcoma of the uterine cervix" OR "uterine cervix leiomyosarcoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Leiomyosarcoma of the cervix uteri" OR "Leiomyosarcoma of cervix uteri" OR "Cervical leiomyosarcoma" OR "leiomyosarcoma of uterine cervix" OR "leiomyosarcoma of the uterine cervix" OR "uterine cervix leiomyosarcoma" OR "sarcoma of cervix uteri"

Recall-expansion terms: sarcoma of cervix uteri

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"leiomyosarcoma"

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (316) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium

Ingested 2026-07-27T09:39:41.057Z